Drug Trial Radar · NCT07773610
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- TASK Applied ScienceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, two-part, multicentre, open label, controlled, randomised clinical trial in adult participants with newly diagnosed, sputum-positive pulmonary drug-sensitive tuberculosis (DSTB). Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis
Conditions
- Tuberculosis, Pulmonary
Interventions
TBAJ-587 50 mgDrug
TBAJ-587LD Tablet 50 mg 100 mg OD TBAJ-587HD Tablet 50 mg 200 mg OD TBAJ-587SD Tablet 50 mg Dose selected from Part A daily
Pretomanid 200mgDrug
Pretomanid Tablet 200 mg 200 mg OD
Linezolid 600Mg TabDrug
600 mg OD
BTZ-043 250 mg or 500 mgDrug
1 000 mg OD
HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)Drug
H 75 mg, R 150 mg, Z 400 mg, E 275 mg fixed dose combination
Quabodepistat (Q) 30 mgDrug
30 mg OD
Ganfeborole 20 mgDrug
20 mg OD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Change in Log10-Transformed Sputum Culture Time to Positivity From Baseline Through Week 8Time frame: From baseline to the end of treatment at 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TASK Brooklyn
Cape Town, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.